Paper Details

  1. Home
  2. Paper Details

Life-threatening pneumonitis after first-line treatment with osimertinib for primary T790M mutated non-small cell lung cancer.

Author: BöckelerMichael, GroßThorben, HaapMichael, HetzelJürgen, HorgerMarius, HäntschelMaik, HäringAlmut, HäringMax-Felix, LewisRichard A, NieblingJohannes, RiessenReimer

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

This study reports a case of life-threatening interstitial lung disease (ILD) during first-line treatment with osimertinib in a patient with EGFR-mutated NSCLC. It emphasizes the importance of recognizing and managing this potential side effect, especially with the increasing use of osimertinib.
Paper Details　
Original Abstract of the Article :
Epithelial growth factor receptor (EGFR) directed tyrosine kinase inhibitor (TKI) treatment is the standard approach in patients with advanced, EGFR-mutated non-small cell lung cancer (NSCLC). Although benefit/risk ratio is favorable for these TKI and side effects are manageable in the vast majority...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327687/

データ提供：米国国立医学図書館（NLM）

Osimertinib: A Double-Edged Sword in Lung Cancer Treatment

[Osimertinib], a [tyrosine kinase inhibitor (TKI)], is a powerful weapon in the fight against [non-small cell lung cancer (NSCLC)]. This study explores a rare but potentially life-threatening side effect of osimertinib: [interstitial lung disease (ILD)]. The researchers report a case of severe ILD developing in a patient with de novo T790M mutated NSCLC during first-line treatment with osimertinib.

The Price of Progress: Managing the Risks of Targeted Therapies

While [osimertinib] offers significant benefits for patients with [EGFR-mutated NSCLC], this case report highlights the importance of vigilance regarding potential side effects. Just as a camel caravan must navigate the desert with caution, avoiding treacherous terrain, healthcare providers need to be aware of the potential risks of new treatments like osimertinib. This case underscores the need for careful monitoring and prompt intervention to manage potential complications.

Navigating the Side Effects of Cancer Treatment: A Balancing Act

This study emphasizes the need for a delicate balance between the potential benefits and risks of [targeted therapies]. While these therapies offer hope for patients, it's crucial to carefully weigh the potential side effects and implement strategies to mitigate them. Imagine a camel caravan crossing a desert with a treasure map in hand; while the treasure is alluring, the journey might be fraught with dangers. Similarly, while targeted therapies offer promise for cancer treatment, it's crucial to navigate the potential side effects with caution and awareness.

Dr. Camel's Conclusion

This case report serves as a reminder that even the most promising treatments can come with potential risks. As we delve deeper into the desert of cancer research, finding solutions that are both effective and safe is paramount. This study highlights the importance of ongoing research to better understand and manage the side effects of new cancer treatments.
Date :
  1. Date Completed 2021-03-11
  2. Date Revised 2022-06-03
Further Info :

Pubmed ID

32374485

DOI: Digital Object Identifier

PMC7327687

Related Literature

Article Analysis
・Side Effects of osimertinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.